ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Nitroglycerin

Also written as “Glyceryl Trinitrate”, “MED2005” and “IMX-150”.

Its studies are mostly in Raynaud Disease · Erectile Dysfunction · Coronary Artery Disease · Fissure in Ano · Connective Tissue Diseases, led by 5 companies.

Drug pageNitroglycerin: every studyMany companies study it; this page follows only the 12 they lead. All 119 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 18, 200712 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediQuest Therapeuticsits history only40 open or runningphase 3since Dec 18, 2007May 29, 2007none ahead
Futura Medical Developments30 open or runningphase 3since Jan 15, 2019Jun 29, 2015none ahead
AbbVieits history only20 open or runningphase 4since Aug 7, 2013Aug 28, 2007none ahead
Procris Pharmaceuticalsits history only20 open or runningphase 2since Mar 17, 2008Mar 17, 2008none ahead
Covis Pharma S.à.r.l.its history only10 open or runningphase 2since Feb 18, 2016Feb 18, 2016none ahead

Also a collaborator on its studies: Merck and Richmond Pharmacology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Futura Medical Developments only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 29, 2015First study: phase 2 study in Erectile DysfunctionFirst studyNCT02495467 · 232 enrolled · United Kingdom
  2. Jan 24, 2018Phase 1 study in Erectile DysfunctionNCT04008732 · 40 enrolled · United Kingdom
  3. Jan 15, 2019Phase 3 study in Erectile DysfunctionNCT03813992 · 1,005 enrolled · Bulgaria, Czechia, Georgia and more

TargetBeta

“Soluble guanylate cyclase activator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ataciguatruleSanofiphase 33
praliciguatruleIronwood Pharmaceuticalsphase 28

Studies

All 3 Futura Medical Developments leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03813992Erectile Dysfunction · Bulgaria, Czechia, Georgia and more3CompletedJul 21, 20191,005
NCT04008732Erectile Dysfunction · United Kingdom1CompletedApr 16, 201840
NCT02495467Erectile Dysfunction · United Kingdom2CompletedJul 30, 2016232

How it is read

Names in the registry

  • “Nitroglycerin”, 4 entries
  • “Glyceryl Trinitrate”, 4 entries
  • “MED2005”, 2 entries
  • “IMX-150”, 2 entries
  • “Nitroglycerin spray”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.